Selective Laser Trabeculoplasty (SLT)

Mr Thomas Ressiniotis answers the top FAQs on Selective Laser Trabeculoplasty (SLT) which is an option used to treat glaucoma.


“The results of a pioneering clinical study conducted by Moorfields Hospital called LIGHT (Laser in Glaucoma and Ocular Hypertension Trial) and published in March 2019 indicated that laser-based treatment in newly diagnosed cases is more successful than the traditional intraocular pressure lowering eye drops.
“This landmark study showed that for 75 per cent of new patients the laser can deliver ‘drop-free’ intraocular pressure control over 36 months with very few if any side-effects. This is achieved by the laser stimulating the body’s own healing response. In effect, the laser is absorbed by pigmented cells in the eye which improves the flow of fluid leading to a reduction in the pressure on the eye” Mr Thomas Ressiniotis, Consultant Ophthalmic Surgeon

Selective Laser Trabeculoplasty (SLT) Consultants